Based on challenges of high clinical and societal relevance and the special competencies of its cooperation partners, HZI has established Research Foci (RF), providing a synergistic, dynamic and flexible framework for the programme.
The Research Foci integrate know-how from different areas of HZI’s research, namely from all three Topics, and can thus address research questions using expertise on pathogens, immune systems and anti-infectives. They offer the flexibility to meet new challenges, e.g. by establishing a new Research Focus when a new urgent problem emerges. Within each Research Focus, HZI scientists pursue the transfer of knowledge from the lab to clinical or pharmaceutical application.
Currently, researchers at HZI and its partner institutions cooperate in seven Research Foci addressing the clinically relevant fields of:
Effective therapies and vaccines are still missing for many pathogens. This is particularly true for vulnerable individuals that are at high risk for severe forms of infection or poor responders to interventions. Thus, the research focus INDI has established experimental and clinical activities to fill the knowledge gaps and develop immune-based approaches to prevent or treat resilient infections in high-risk patients. This research contributes to a better understanding of host responses to infections and vaccinations.
The most important questions for RF INDI are:
- Why do individuals respond so differently to infections, vaccinations and treatments? What is the contribution of hereditary traits, and what is environmentally dependent?
- How can studies of vulnerable individuals be used to develop novel immune-based interventions?
- Which parameters predict the efficacy of immune responses?
- How to design vaccines and immunotherapies to increase their efficiency of immune protection in vulnerable individuals and populations?
Speaker RF INDI: Prof Dr Jochen Hühn
Deputy Speaker RF INDI: Prof Dr Markus Cornberg
Frenz,T., Grabski,E., Buschjager,D., Vaas,L.A., Burgdorf,N., Schmidt,R.E., Witte,T., and Kalinke,U. (2016). CD4 T cells in patients with chronic inflammatory rheumatic disorders show distinct levels of exhaustion. J Allergy Clin. Immunol. 138, 586-589.
Lipps,C., Klein,F., Wahlicht,T., Seiffert,V., Butueva,M., Zauers,J., Truschel,T., Luckner,M., Köster,M., MacLeod,R., Pezoldt,J., Hühn,J., Yuan,Q., Muller,P.P., Kempf,H., Zweigerdt,R., Dittrich-Breiholz,O., Pufe,T., Beckmann,R., Drescher,W., Riancho,J., Sanudo,C., Korff,T., Opalka,B., Rebmann,V., Gothert,J.R., Alves,P.M., Ott,M., Schucht,R., Hauser,H., Wirth,D., and May,T. (2018). Expansion of functional personalized cells with specific transgene combinations. Nat. Commun. 9, 994.
Lirussi,D., Ebensen,T., Schulze,K., Trittel,S., Duran,V., Liebich,I., Kalinke,U., and Guzmán,C.A. (2017). Type I IFN and not TNF, is Essential for Cyclic Di-nucleotide-elicited CTL by a Cytosolic Cross-presentation Pathway. EBioMedicine. 22, 100-111.
Raud,B., Roy,D.G., Divakaruni,A.S., Tarasenko,T.N., Franke,R., Ma,E.H., Samborska,B., Hsieh,W.Y., Wong,A.H., Stüve,P., Arnold-Schrauf,C., Guderian,M., Lochner,M., Rampertaap,S., Romito,K., Monsale,J., Brönstrup,M., Bensinger,S.J., Murphy,A.N., McGuire,P.J., Jones,R.G., Sparwasser,T., and Berod,L. (2018). Etomoxir Actions on Regulatory and Memory T Cells Are Independent of Cpt1a-Mediated Fatty Acid Oxidation. Cell Metab. 28, 504-515.
Soon,C.F., Behrendt,P., Todt,D., Manns,M.P., Wedemeyer,H., Sallberg,C.M., and Cornberg,M. (2019). Defining Virus-specific CD8+ TCR Repertoires for Therapeutic Regeneration of T Cells against Chronic Hepatitis E. J. Hepatol. Epub ahead of print.